Company intelligence / Profile preview
CASI Pharmaceuticals, Inc.
Beijing, Chinacasipharmaceuticals.com ↗
- Ownership
- Public · CASI
- Employees
- ~233
- Development stage
- Preclinical
01
Overview
CASI Pharmaceuticals has commercialized EVOMELA for multiple myeloma in China. The company is developing CID-103, an anti-CD38 monoclonal antibody for organ transplant rejection and autoimmune diseases, with a focus on addressing antibody-mediated rejection (AMR) in transplant patients.
- Therapeutic areas
- OncologyImmunology
- Modalities
- Monoclonal antibodiesCAR-T therapySmall molecules
- Industry
- Biotech
02
Drug pipeline
14 assets13 more assets in the full pipeline.
03
Partnerships
Juventas Cell Therapy Ltd.BioInvent International ABBlack Belt Therapeutics LimitedCleave Therapeutics, Inc.Acrotech Biopharma L.L.C.Mundipharma International Corporation Limited
Beyond the preview
Go deeper on CASI Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CASI Pharmaceuticals, Inc..